The estimated Net Worth of Nancy A. Grygiel is at least 4.66 百万$ dollars as of 3 May 2024. Ms Grygiel owns over 2,117 units of AMGEN stock worth over 3,261,192$ and over the last 4 years she sold AMGN stock worth over 1,395,062$.
Sign up
Ms Grygiel AMGN stock SEC Form 4 insiders trading
Ms has made over 4 trades of the AMGEN stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 2,117 units of AMGN stock worth 662,812$ on 3 May 2024.
The largest trade she's ever made was exercising 2,500 units of AMGEN stock on 11 May 2021 worth over 406,500$. On average, Ms trades about 242 units every 36 days since 2020. As of 3 May 2024 she still owns at least 9,883 units of AMGEN stock.
You can see the complete history of Ms Grygiel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Nancy A. Grygiel biography
Nancy A. Grygiel is the Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer at AMGEN.
How old is Ms Grygiel?
Ms Grygiel is 53, she's been the Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer of AMGEN since . There are 21 older and 2 younger executives at AMGEN. The oldest executive at AMGEN Inc. is Fred Hassan, 74, who is the Independent Director.
What's Ms Grygiel's mailing address?
Nancy's mailing address filed with the SEC is ONE AMGEN CENTER DRIVE, , THOUSAND OAKS, CA, 91320.
Insiders trading at AMGEN
Over the last 21 years, insiders at AMGEN have traded over 219,663,137$ worth of AMGEN stock and bought 8,904 units worth 919,219$ . The most active insiders traders include Robert Eckert、Kevin W Sharer、Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of 8,732,261$. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth 662,812$.
What does AMGEN do?
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
What does AMGEN's logo look like?
Complete history of Ms Grygiel stock trades at AMGEN
AMGEN executives and stock owners
AMGEN executives and other stock owners filed with the SEC include:
-
Robert Bradway,
Chairman of the Board, President, Chief Executive Officer -
Jonathan Graham,
Senior Vice President, General Counsel, Secretary -
Murdo Gordon,
Executive Vice President of Global Commercial Operations -
David Reese,
Executive Vice President - Research and Development -
Robert A. Bradway,
Chairman, CEO & Pres -
Murdo Gordon,
Exec. VP of Global Commercial Operations -
Dr. David M. Reese M.D.,
Exec. VP of R&D -
Esteban Santos,
Exec. VP of Operations -
Peter H. Griffith,
Exec. VP & CFO -
Robert Eckert,
Lead Independent Director -
Gregory Garland,
Independent Director -
Ronald Sugar,
Independent Director -
Charles Holley,
Independent Director -
Wanda Austin,
Independent Director -
Brian Druker,
Independent Director -
Fred Hassan,
Independent Director -
Robert Williams,
Independent Director -
Tyler Jacks,
Independent Director -
Ellen Kullman,
Independent Director -
Amy Miles,
Independent Director -
Linda Louie,
Vice President - Finance, Chief Accounting Officer -
David Piacquad,
Senior Vice President - Business Development -
Lori Johnston,
Senior Vice President - Human Resources -
Cynthia Patton,
Senior Vice President, Chief Compliance Officer -
Esteban Santos,
Executive Vice President, Operations -
Peter Griffith,
Chief Financial Officer, Executive Vice President -
Nancy A. Grygiel,
Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer -
Jonathan P. Graham,
Exec. VP, Gen. Counsel & Sec. -
Arvind Sood,
VP of Investor Relations -
Mike Zahigian,
Sr. VP & Chief Information Officer -
Linda H. Louie,
VP of Fin. & Chief Accounting Officer -
Annette Louise Such,
CAO -
Frank Biondi,
Director -
Greg C. Garland,
Director -
Frank C Herringer,
Director -
David W Meline,
EVP & CFO -
Anthony C Hooper,
EVP, Global Commercial Ops. -
R Sanders Williams,
Director -
Rebecca M Henderson,
Director -
Judith C Pelham,
Director -
David Baltimore,
Director -
Sean E Harper,
EVP, Research & Development -
Carbonnel Francois De,
Director -
James E. Bradner,
EVP, R&D, & Chief Sci. Officer -
Nancy A. Grygiel,
SVP & CCO -
Thomas James Flanagan,
Sr VP & CIO -
Leonard D Schaeffer,
Director -
Jonathan M Peacock,
CFO -
Gilbert S Omenn,
Director -
J Paul Reason,
Director -
Thomas J.W. Dittrich,
VP, Finance & CAO -
David J Scott,
Sr. VP, Gen. Counsel & Secy. -
A Kelly Michael,
VP Corp Plng & Control & CAO -
Stuart A Tross,
SVP, Human Resources -
Kevin W Sharer,
Chairman of the Bd, CEO & Pres -
Vance D Coffman,
Director -
David W Beier,
SVP Global Govt & Corp Affairs -
Fabrizio Bonanni,
Senior VP, Manufacturing -
Anna Richo,
SVP & CCO -
Jerry D Choate,
Director -
Frederick W Gluck,
Director -
Roger M Perlmutter,
Exec VP Research & Development -
George J Morrow,
Exe VP, Global Commercial Ops -
Brian M Mcnamee,
Sr. V.P. Human Resources -
Richard D Nanula,
Exe VP Fin, Strat & Comm & CFO -
Franklin P Jr Johnson,
Director -
Donald B Rice,
Director -
Dennis M Fenton,
Executive Vice President -
Hassan Dayem,
Sr. V.P. & Chief Info. Officer -
Barry D Schehr,
VP Financial Ops & CAO -
Edward V Fritzky,
Director -
Steven M Odre,
Sr. VP, Gen. Cousel & Secy. -
Timothy O Martin,
V.P., Planning and Control -
Beth C Seidenberg,
Sr VP Development -
Willard H Dere,
Sr. V.P., Global Dev & CMO -
Joseph P Miletich,
Sr VP Rsch & Preclinical Dev -
Patricia C Sueltz,
Director -
Steven Lazarus,
Director -
Derek Miller,
SVP, Human Resources -
Omar Ishrak,
Director -
Rachna Khosla,
SVP, Business Development -
Michael V Drake,
Director -
Matthew C. Busch,
VP, Finance & CAO -
Mary E. Klotman,
Director